Datopotamab deruxtecan improves progression-free survival to 10.8 months versus 5.6 months in TNBC
Trial shows datopotamab deruxtecan improves survival in triple-negative breast cancer
This Phase III randomized controlled trial of 644 patients with untreated, locally recurrent inoperable or metastatic triple-negative breast…
A new trial shows that datopotamab deruxtecan may extend progression-free and overall survival for patients with advanced triple-negative br…
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free